Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001-Reference-Cited by-同舟云学术

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Published:2019-04 Issue:4 Volume:30 Page:582-588
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hamid O.,Robert C.,Daud A.,Hodi F.S.,Hwu W.J.,Kefford R.,Wolchok J.D.,Hersey P.,Joseph R.,Weber J.S.,Dronca R.,Mitchell T.C.,Patnaik A.,Zarour H.M.,Joshua A.M.,Zhao Q.,Jensen E.,Ahsan S.,Ibrahim N.,Ribas A.

Funder

Merck & Co.

Merck Sharp & Dohme Corp.

Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/4/582/28564963/mdz011.pdf

Reference29 articles.

1. Management of melanoma;Corrie;Br Med Bull,2014

2. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

3. National Comprehensive Cancer Network I. NCCN Clinical Practice Guidelines in Oncology – Melanoma,2018

4. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

Cited by 669 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

3. Long-Term Results of Treatment of Patients with Stage IV Malignant Melanoma in the Sverdlovsk Region;Ural Medical Journal;2024-09-03

4. Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects;Critical Reviews in Oncology/Hematology;2024-09

5. Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy;Journal of Experimental & Clinical Cancer Research;2024-08-15